Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference.

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study.

The most fun image & video creation tool in the world is here. Try it for free in the Grok App.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025.

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China.

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025.

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China.

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference.

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC. FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLC. Topline data from the HARMONi Trial Is Expected in Mid-2025.

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024.

Summit Therapeutics Raises $235 Million. Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement. $235 Million in Net Proceeds Raised at Sept 11 2024 Closing Price of $22.70.

RT @CNBCFastMoney: Summit Therapeutics $SMMT shares nearly doubling this week after its lung cancer drug beat Merck's Keytruda in a head-to….

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China.

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at #WCLC24 . Additionally, Ivonescimab Phase II Data in Perioperative Setting for Resectable NSCLC to be Presented at IASLC's World Lung.

We are excited to begin our collaboration with @MDAndersonNews to accelerate the development of ivonescimab.

Summit Therapeutics and MD Anderson (@MDAndersonNews) Announce Strategic Collaboration to Accelerate Development of Ivonescimab. Five Year Collaboration Intended to Advance PD-1 / VEGF Bispecific in Several Solid Tumors across Multiple Clinical Trials.

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors.

Summit Raises $200 Million at Premium to Previous Closing Price. In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa.

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA.

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy.

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China.